新型蛋白酶体抑制剂伊沙佐米对多发性骨髓瘤的研究进展

Research advance of novel proteasome inhibitor ixazomib on multiple myeloma

目的探究新型蛋白酶体抑制剂伊沙佐米对多发性骨髓瘤(multiple myeloma,MM)的治疗作用。方法对近年来相关文献进行归纳,分析并总结伊沙佐米治疗多发性骨髓瘤的作用机制及研究进展。结果蛋白酶体抑制剂(proteasome inhibitors,PIs)是近年来应用于MM的主要治疗药物。伊沙佐米作为首个被美国食品药品监督管理局(FDA)批准的口服PIs,可联合来那度胺和地塞米松用于复发性和(或)难治性或新诊断MM患者。该联合方案为中国首个含有PIs的全口服治疗方案,其临床疗效已获得初步认可。结论伊沙佐米及其联合方案可有效治疗MM,给患者带来良好的临床获益。

Objective To explore the therapeutic effects of ixazomib,a new proteasome inhibitor,on multiple myeloma(MM).Methods According to the relevant literature in recent years,the mechanism and research progress of ixazomib in MM were summarized and analyzed.Results Proteasome inhibitors(PIs) were the main therapeutic drugs used in MM.Ixazomib,the first oral PIs approved by the U.S. Food and Drug Administration(FDA),was combined with lenalidomide and dexamethasone for patients with relapsed and/or refractory or newly diagnosed MM.The combination regimen of ixazomib was the first full oral treatment regimen containing PIs in China,and its clinical efficacy has been initially recognized.Conclusion Ixazomib and its combination regimen can treat MM effectively and bring good clinical benefits to patients.